Lineage Cell Therapeutics Inc
F:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
8
|
8x8 Inc
XMUN:EGT
|
US |
|
Willow Biosciences Inc
F:3D7
|
CA |
|
V
|
Vinci SA
OTC:VCISY
|
FR |
|
Coveo Solutions Inc
TSX:CVO
|
CA |
|
S
|
Societe BIC SA
DUS:BIF
|
FR |
|
O
|
Oracle Corp
DUS:ORC
|
US |
|
K
|
Kering SA
DUS:PPX
|
FR |
|
Telekom Austria AG
F:TA1
|
AT |
|
U
|
UniCredit SpA
OTC:UNCFF
|
IT |
|
O
|
Olympia Financial Group Inc
TSX:OLY
|
CA |
|
T
|
Tile Shop Holdings Inc
F:2TS
|
US |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BT3 is 5.693 EUR with a low forecast of 3.075 EUR and a high forecast of 9.59 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
5.693
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 5.693 EUR with a low forecast of 3.075 EUR and a high forecast of 9.59 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
48%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 48%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
57%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 3 years is 57%.
